Genocea Biosciences Inc. (GNCA) Given Buy Rating at Needham & Company LLC
Genocea Biosciences Inc. (NASDAQ:GNCA)‘s stock had its “buy” rating reiterated by investment analysts at Needham & Company LLC in a note issued to investors on Thursday. They currently have a $15.00 price objective on the stock. Needham & Company LLC’s price target would indicate a potential upside of 236.32% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research report on Tuesday, July 5th. FBR & Co reissued a “buy” rating on shares of Genocea Biosciences in a research report on Friday, June 10th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Genocea Biosciences has a consensus rating of “Buy” and a consensus target price of $16.96.
Shares of Genocea Biosciences (NASDAQ:GNCA) traded down 0.22% during midday trading on Thursday, hitting $4.45. The stock had a trading volume of 250,353 shares. The company’s 50 day moving average price is $5.35 and its 200-day moving average price is $4.73. Genocea Biosciences has a 1-year low of $2.56 and a 1-year high of $8.20. The firm’s market capitalization is $126.09 million.
Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.05. Genocea Biosciences had a negative net margin of 5,121.17% and a negative return on equity of 47.87%. Equities analysts predict that Genocea Biosciences will post ($1.63) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. raised its position in shares of Genocea Biosciences by 37.0% in the first quarter. Franklin Resources Inc. now owns 2,886,600 shares of the company’s stock worth $22,342,000 after buying an additional 779,400 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in shares of Genocea Biosciences during the first quarter worth approximately $662,000. Paloma Partners Management Co bought a new position in shares of Genocea Biosciences during the second quarter worth approximately $334,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Genocea Biosciences during the first quarter worth approximately $565,000. Finally, Vanguard Group Inc. raised its position in shares of Genocea Biosciences by 9.5% in the second quarter. Vanguard Group Inc. now owns 656,515 shares of the company’s stock worth $2,691,000 after buying an additional 57,062 shares during the period. Institutional investors and hedge funds own 56.49% of the company’s stock.
About Genocea Biosciences
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.